Ocuphire Pharma Research and Development Expenses 2010-2024 | IRD

Ocuphire Pharma research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Ocuphire Pharma Annual Research and Development Expenses
(Millions of US $)
2023 $18
2022 $14
2021 $15
2020 $17
2019 $2
2018 $13
2017 $11
2016 $10
2015 $12
2014 $7
2013 $3
2012 $3
2011 $12
2010 $4
2009 $3
Ocuphire Pharma Quarterly Research and Development Expenses
(Millions of US $)
2024-06-30 $6
2024-03-31 $5
2023-12-31 $4
2023-09-30 $3
2023-06-30 $5
2023-03-31 $6
2022-12-31 $4
2022-09-30 $3
2022-06-30 $3
2022-03-31 $5
2021-12-31 $5
2021-09-30 $3
2021-06-30 $4
2021-03-31 $3
2020-12-31 $13
2020-09-30 $1
2020-06-30 $1
2020-03-31 $2
2019-12-31 $-3
2019-09-30 $1
2019-06-30 $2
2019-03-31 $2
2018-12-31 $3
2018-09-30 $3
2018-06-30 $3
2018-03-31 $4
2017-12-31 $3
2017-09-30 $3
2017-06-30 $3
2017-03-31 $2
2016-12-31 $2
2016-09-30 $2
2016-06-30 $2
2016-03-31 $3
2015-12-31 $3
2015-09-30 $3
2015-06-30 $3
2015-03-31 $3
2014-12-31 $2
2014-09-30 $2
2014-06-30 $2
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31
2011-12-31 $1
2011-09-30 $2
2011-06-30 $5
2011-03-31 $3
2010-12-31 $1
2010-09-30 $1
2010-06-30 $1
2010-03-31 $0
2009-12-31 $1
2009-09-30 $0
2009-06-30 $1
2009-03-31 $1
Sector Industry Market Cap Revenue
$0.000B $0.000B
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
Stock Name Country Market Cap PE Ratio
Fanhua (AIFU) China $0.086B 2.07
Top KingWin (WAI) China $0.008B 0.00
S&W Seed (SANW) United States $0.006B 0.00
Invo BioScience (NAYA) United States $0.004B 0.00